Radical Prostatectomy Offers Excellent Long-Term Outcomes

Share this content:
Radical prostatectomy is associated with excellent long-term outcomes in patients with localized prostate cancer.
Radical prostatectomy is associated with excellent long-term outcomes in patients with localized prostate cancer.

NEW ORLEANS—Radical prostatectomy (RP) is associated with excellent long-term outcomes in patients with localized prostate cancer (PCa), Italian researchers reported at the 2015 American Urological Association annual meeting.

In a study of 529 PCa patients who underwent RP from 1985–1994, Giorgio Gandaglia, MD, of IRCCS Ospedale San Raffaele in Milan, and colleagues found that overall 20-year rates of biochemical recurrence (BCR)-free, clinical recurrence-free, and cancer-specific survival were 55.1%, 71.6%, and 78.2%, respectively.

The median follow-up for survivors was 168 months. The 5-year BCR-free survival rates increased according to the time elapsed between surgery and patient evaluation: the rates were 87.3%, 89.2%, 89.5%, 92.0%, and 92.5% when the time elapsed was 1, 2, 3, 4, and 5 years, respectively, Dr. Gandaglia's group reported. The median time from BCR to cancer-specific mortality (CSM) was 79 months.

RELATED: Post-Prostatectomy Outcomes Differ for Gleason 8, 9-10 Prostate Cancer

In multivariate analysis, time from surgery to BCR was a significant predictor of CSM. Patients experiencing BCR after 10 years from surgery remained at higher risk of CSM compared with their counterparts free from recurrence at the same point, even after adjusting for the risk of other-cause mortality.

CSM rates increased along with D'Amico risk groups and age. For example, the rate was 3.3% for low-risk patients younger than 65 years and 30.9% for high-risk patients aged 65 years and older.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters